Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

There is always a challenging moment in every investor’s favorite stock and portfolio, especially when said businesses are ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Hims & Hers (NYSE: HIMS) and UnitedHealth (NYSE: UNH) suffered huge stock price decreases that attracted investors looking to buy the dip. *Stock prices used were the afternoon prices of June 28, 2025 ...

Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...

你有没有想过，减肥药市场的风云变幻，背后隐藏着怎样的故事？最近，诺和诺德与远程医疗平台Hims&Hers的短暂合作引发了行业的广泛关注。58天的“闪婚闪离”不仅让人感到意外，更是暴露了当前减肥药市场的种种危机！

你是否曾经试图减肥，却发现效果不尽如人意？如今，随着越来越多的减肥药物进入市场，减肥变得似乎不再那么困难。然而，最近的一则消息却引发了广泛关注：诺和诺德 (NVO.US)终止了与远程医疗公司Hims & Hers ...

智通财经APP获悉，在诺和诺德(NVO.US)终止与远程医疗公司Hims & Hers Health合作后，摩根士丹利发布研报给予Hims & Hers ...

Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

摩根士丹利 分析师在研报中指出，Hims & Hers Health面临的核心问题在于，若 诺和诺德 对其发起诉讼，该公司能否继续提供复合式GLP-1药物疗法。